Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: A randomized, double-blind, placebo-controlled, phase IIb study

Fertility and Sterility

Volumn 95, Issue 2, 2011, Pages

  Nieman, Lynnette K ^a   Blocker, Wendy ^a   Nansel, Tonja ^a   Mahoney, Sheila ^a   Reynolds, James ^b   Blithe, Diana ^a   Wesley, Robert ^c   Armstrong, Alicia ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b Mark O Hatfield Clinical Research Center   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

fibroids; Selective progestin receptor modulator; UFS QOL; ulipristal acetate

Indexed keywords

HEMOGLOBIN; PLACEBO; ULIPRISTAL;

ABDOMINAL PAIN; ADRENAL DISEASE; ADULT; AMENORRHEA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BLOATING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART ARRHYTHMIA; HOT FLUSH; HUMAN; HYDROCORTISONE URINE LEVEL; KNEE PAIN; MASTALGIA; MENSTRUATION DISORDER; MOOD; MOOD CHANGE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PELVIS PAIN SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SPOTTING; STRUCTURED QUESTIONNAIRE; TUMOR VOLUME; UTERUS MYOMA; VAGINA DISCHARGE;

EID: 78751569564     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2010.09.059     Document Type: Article

References (32)

1. J. Mauskopf, M. Flynn, P. Thieda, J. Spalding, and J. Duchane The economic impact of uterine fibroids in the United States: a summary of published estimates J Women's Health (2002) 14 2005 692 703
2. V.S. Williams, G. Jones, J. Mauskopf, J. Spalding, and J. DuChane Uterine fibroids: a review of health-related quality of life assessment J Women's Health (2002) 15 2006 818 829
3. R.A. Bucek, S. Puchner, and J. Lammer Mid- and long-term quality-of-life assessment in patients undergoing uterine fibroid embolization AJR 186 2006 877 882
4. K.E. Hartmann, H. Birnbaum, R. Ben-Hamadi, E.Q. Wu, M.H. Farrell, and J. Spalding Annual costs associated with diagnosis of uterine leiomyomata Obstet Gynecol 108 2006 930 937
5. D. Lerner, F. Mirza, H. Chang, K. Renzulli, K. Perch, and D. Chelmow Impaired work performance among women with symptomatic uterine fibroids J Occup Environ Med/Am Col Occup Environ Med 50 2008 1149 1157
6. B.J. Attardi, J. Burgenson, S.A. Hild, and J.R. Reel In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone J Steroid Biochem Mol Biol 88 2004 277 288
7. E.D. Levens, C. Potlog-Nahari, A.Y. Armstrong, R. Wesley, A. Premkumar, and D.L. Blithe CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial Obstet Gynecol 111 2008 1129 1136
8. Bulletin AT. Uterine leiomyomata. Number 192 - May 1994. ACOG technical bulletin. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics 1994;46:73-82.
9. J.E. Ware Jr., and B. Gandek Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) project J Clin Epidemiol 51 1998 903 912
10. J.B. Spies, K. Coyne, N. Guaou Guaou, D. Boyle, K. Skyrnarz-Murphy, and S.M. Gonzalves The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata Obstet Gynecol 99 2002 290 300
11. R.W. Noyes, and J. Rock Dating the endometrial biopsy Fertil Steril 1 1950 3 25
12. J.E. Ware, KM, and J.E. Dewey How to score version two of the SF-36 Health Survey 2000 QualityMetric Incorporated Lincoln, RI
13. G.L. Mutter, C. Bergeron, L. Deligdisch, A. Ferenczy, M. Glant, and M. Merino The spectrum of endometrial pathology induced by progesterone receptor modulators Mod Pathol 21 2008 591 598
14. J.V. Lacey Jr., G.L. Mutter, M.R. Nucci, B.M. Ronnett, O.B. Ioffe, and B.B. Rush Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies Cancer 113 2008 2073 2081
15. B. Kessel, J. Liu, J. Mortola, S. Berga, and S.S. Yen Treatment of uterine fibroids with agonist analogs of gonadotropin-releasing hormone Fertil Steril 49 1988 538 541
16. S. Palomba, M. Pellicano, P. Affinito, C. Di Carlo, F. Zullo, and C. Nappi Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy Fertil Steril 75 2001 429 433
17. G. Bianchi, S. Costantini, P. Anserini, G. Rovetta, P. Monteforte, and M.V. Menada Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density Maturitas 11 1989 179 185
18. M.C. Batista, T.P. Cartledge, A.W. Zellmer, M.J. Merino, C. Axiotis, and D.L. Loriaux Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy Am J Obstet Gynecol 167 1992 60 65
19. N. Chabbert-Buffet, A. Pintiaux-Kairis, and P. Bouchard Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial J Clin Endocrinol Metab 92 2007 3582 3589
20. S.H. Eisinger, J. Fiscella, T. Bonfiglio, S. Meldrum, and K. Fiscella Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata Eur J Obstet Gynecol Reprod Biol 146 2009 215 218
21. M. Engman, S. Granberg, A.R. Williams, C.X. Meng, P.G. Lalitkumar, and K. Gemzell-Danielsson Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial Hum Reprod (Oxford, England) 24 2009 1870 1879
22. M. Bagaria, A. Suneja, N.B. Vaid, K. Guleria, and K. Mishra Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial Aust N Z J Obstet Gynaecol 49 2009 77 83
23. J.L. Carbonell Esteve, R. Acosta, B. Heredia, Y. Perez, M.C. Castaneda, and A.V. Hernandez Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial Obstet Gynecol 112 2008 1029 1036
24. K. Fiscella, S.H. Eisinger, S. Meldrum, C. Feng, S.G. Fisher, and D.S. Guzick Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial Obstet Gynecol 108 2006 1381 1387
25. S.H. Eisinger, T. Bonfiglio, K. Fiscella, S. Meldrum, and D.S. Guzick Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas J Min Invas Gynecol 12 2005 227 233
26. A.A. Murphy, A.J. Morales, L.M. Kettel, and S.S. Yen Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect Fertil Steril 64 1995 187 190
27. C. Zeng, M. Gu, and H. Huang [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone] Zhonghua fu chan ke za zhi 33 1998 490 492
28. M. Dueholm, E. Lundorf, E.S. Hansen, S. Ledertoug, and F. Olesen Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas Am J Obst Gynecol 186 2002 409 415
29. K. Fiscella, and S. Eisinger CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial Obstet Gynecol 112 2008 707 [author reply: 707-8]
30. H. Ishikawa, S. Reierstad, M. Demura, A.W. Rademaker, T. Kasai, and M. Inoue High aromatase expression in uterine leiomyoma tissues of African-American women J Clin Endocrinol Metab 94 2009 1752 1756
31. E.E. Othman, and A. Al-Hendy Molecular genetics and racial disparities of uterine leiomyomas Best Pract Res Clin Obstet Gynaecol 22 2008 589 601
32. I.M. Spitz Progesterone antagonists and progesterone receptor modulators: an overview Steroids 68 2003 981 993